期刊文献+

乳腺癌基因分型与血清肿瘤标志物表达的相关性分析 被引量:17

Correlation Analysis Between Genotyping of Breast Cancer and Expression of Serum Tumor Markers
原文传递
导出
摘要 目的探讨乳腺癌基因分型与血清肿瘤标志物之间的相关性。方法选取2013年1月—2015年12月的106例乳腺癌患者,免疫组化检测ER、PR、c-erbB-2,采用电化学发光法对肿瘤标志物进行检测,单因素方差分析是否存在显著性差异。结果细胞角蛋白十九片段、铁蛋白、癌胚抗原、糖类抗原724在Luminal A型乳腺癌组血清中有较高水平的表达,明显高于其他3种基因分型,差异有统计学意义(P<0.05);糖类抗原125、糖抗原153在Luminal A型和Basal-like型乳腺癌组血清中有较高水平的表达,明显高于另2种基因分型,差异有统计学意义(P<0.05);其他肿瘤标志物在不同基因分型中差异无统计学意义。结论乳腺癌患者血清中细胞角蛋白十九片段、铁蛋白、癌胚抗原、糖类抗原724、糖类抗原125、糖类抗原153水平与乳腺癌基因型有相关性。 OBJECTIVE To investigate the correlation between genotyping of breast cancer and blood serum tumor markers. METHODS The serum tumors markers were examined by electrochemistry illumination and radioimmunoassay in 106 patients with breast cancer from January 2013 to December 2015, ER, PR and c-erb B-2 were detected by immunohistochemistry. Tumor markers were detected by electrochemiluminescence, one-way ANOVA was used to decide significant differences in categories. RESULTS Increase of serum CYFRA21-1, FER, CEA, CA724 level was correlated with Luminal A, significantly higher than the other 3 genotyping, the difference was statistically significant(P〈0.05). CA125, CA153 level was correlated with Luminal A and Basal-like, significantly higher than the other 2 genotyping, the difference was statistically significant(P〈0.05). There were no significant differences in other tumor markers in different genotypes. CONCLUSION CYFRA21-1, FER, CEA, CA724, CA125, CA153 level in breast cancer have correlation with genotyping.
作者 张美玲 董恒进 ZHANG Meiling DONG Hengjin(Zhejiang University, Hangzhou 310058, China Department of Pharmacy, Tongde Hospital of Zhejiang Province, Hangzhou 310012, China)
出处 《中国现代应用药学》 CAS CSCD 2017年第1期111-115,共5页 Chinese Journal of Modern Applied Pharmacy
关键词 乳腺癌 基因分型 肿瘤标志物 相关分析 breast cancer genotyping tumor markers correlation analysis
  • 相关文献

参考文献4

二级参考文献59

  • 1陆巍,陆维祺,何国杰,郑树.肿瘤和正常组织中细胞角蛋白CK19的表达差异及其意义分析[J].中国临床医学,2007,14(1):115-117. 被引量:4
  • 2Smith RA, Saslow D, Sawyer KA, et al. American cancersociety guidelines for breast cancer screening:, update 2003. CA Cancer J Clin, 2003, 53(3):141-169. 被引量:1
  • 3Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer, 2003, 3(4):243-252. 被引量:1
  • 4Dufy MJ, Shering S. CA 153: apregnostic marker in breast cancer. Int Markers, 2000,15(4):330-333. 被引量:1
  • 5DONG L, XU X M, YU J N. Summarize ontraditional Chinese medicine cataplasm research [J].中国药师, 2011, 14(1): 129-131. 被引量:1
  • 6Foulkes WD, Smith IE, Reis- filho JS. Triple- negative breast cancer[ J ]. New England journal of medicine ,2010 ; 363 (20) : 1938-1948. 被引量:1
  • 7Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors [ J ]. Nature, 2000 ; 4 ( 6 ) :747-752. 被引量:1
  • 8Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer : highlights of the St gallen international expert consensus on the primary therapy of early breast cancer,2013 [ J]. Ann Oncol,2013 ; 24(9) :2206-2223. 被引量:1
  • 9Lehmann BD, Pietenpol JA. Identification and in treatment strategies for triple-negative breast cancer subtypes [ J]. J Pathol,2014 ;232( 2 ) :142-150. 被引量:1
  • 10Prat A, Adamo B, Cheang MC, et al. Molecular characterization of basal-like and non-basal-like triple- negative breast cancer [ J ]. The oncologist, 2013 ; 18 ( 2 ) : 123-133. 被引量:1

共引文献36

同被引文献146

引证文献17

二级引证文献120

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部